All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
APVO436 has been granted Orphan Drug Designation (ODD) for the treatment of patients with acute myeloid leukemia (AML) by the United States Food and Drug Administration (FDA).1 APVO436 is a bispecific antibody that is currently under investigation in patients with AML and myelodysplastic syndrome (MDS) in a phase I/Ib trial (NCT03647800).
APVO436 redirects T-cell cytotoxicity to tumor cells by targeting CD123 and CD3. APVO436 was developed using a proprietary platform, which can produce targeted bispecific antibodies with the ability to achieve potent biological activity and extended half-life. These antibodies can be used at lower concentrations than other bispecific antibody formats and can be built with a range of mechanisms of action.
ODD status means that a company is eligible to a seven-year exclusive marketing period and allows applications for funding for phase I and II clinical trials, with reduced market application filing fees and quicker regulatory processing.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
How important to you is the turnaround time for genetic testing in guiding your initial treatment decisions?